COACH Trial Confirms Durable Benefits in Achondroplasia
Topline at 52 weeks from Ascendis’ Phase 2 COACH study in pediatric achondroplasia showed mean annualized growth velocity of...
Jon Napitupulu
Benitec BB-301 Trial Shows Positive Long-Term Efficacy
Topline data: In Benitec’s Phase 1b/2a OPMD study, the first treated patient showed sustained and deepening benefit at 24...
Phase 1 Trial of AGENT-797 to Prevent Graft-vs-Host Disease
MiNK Therapeutics will open an investigator-sponsored Phase 1 trial of its off-the-shelf iNKT cell therapy, agenT-797, in allogeneic hematopoietic...
Marius Pharma to Study Kyzatrex in Men Ages 65-80
In its prior Phase 3 program, KYZATREX achieved normal 24-hour mean total testosterone levels in 88% of treated hypogonadal...
U of T Study: Real-Time Brain Fluid Modulation with Light
A brief, 4-minute session of near-infrared photobiomodulation produced immediate fMRI-detected shifts in cerebrospinal fluid dynamics in healthy adults, including...
ALX Oncology Advances Trials for Evorpacept and ALX2004
No dose-limiting toxicities have been observed to date in ALX Oncology’s first-in-human study of its EGFR-targeted ADC ALX2004, which...
ACTG Launches iPACE-HIV Study on Frailty Intervention
ACTG has opened enrollment for A5426 (IPACE-HIV), a Phase 2, double-blind, randomized study testing the senolytic combination of dasatinib...
Regenera Device May Transform Breast Reconstruction After Trial
Topline data: In a 94-patient pivotal trial in lumpectomy patients receiving adjuvant therapy, Tensive’s REGENERA bioresorbable scaffold met its...
Krystal Biotech Gives Update on Phase 1 Cystic Fibrosis Trial
No efficacy or safety data have been disclosed yet. Krystal Biotech will present an interim look at the highest-dose...
Pulmocide Terminates Phase 3 Opera-T Study of Opelconazole
Interim data from Opera-T showed a numerically lower Day 84 favorable response rate and a numerically higher mortality rate...